The Stryker hip replacement lawsuit represents one of the largest medical device litigation cases in U.S. history, with settlements exceeding $2 billion across multiple defective hip implant products. If you received a Stryker Rejuvenate, ABG II, LFIT V40, or Tritanium hip implant and experienced complications requiring revision surgery, you may be eligible for compensation ranging from $300,000 to $600,000 or more depending on your circumstances. The $300,000 minimum base award established in the Rejuvenate/ABG II settlement stands as the largest ever recorded in failed hip replacement litigation.
The litigation spans multiple devices and settlement phases, beginning with Stryker’s voluntary recall of the Rejuvenate and ABG II hip stems in July 2012. A landmark $1.43 billion global settlement followed in fall 2014, resolving thousands of claims from patients who suffered metal poisoning, bone destruction, and painful device failures. For example, patients who received the Rejuvenate modular hip stem often experienced corrosion at the junction between the neck and stem components, releasing chromium and cobalt particles into surrounding tissue and bloodstream. This article covers the history of Stryker hip implant failures, current pending litigation, settlement amounts and eligibility requirements, the ongoing Tritanium acetabular shell lawsuits, and practical guidance for those considering legal action.
Table of Contents
- What Devices Are Included in the Stryker Hip Replacement Lawsuit?
- The $1.43 Billion Rejuvenate and ABG II Settlement Explained
- LFIT V40 Litigation and Confidential Settlement Terms
- Tritanium Acetabular Shell: The Ongoing Battle
- Eligibility Requirements and Compensation Factors
- Statute of Limitations and Filing Deadlines
- What to Expect From the Legal Process
- Future of Stryker Hip Litigation
- Conclusion
What Devices Are Included in the Stryker Hip Replacement Lawsuit?
Four primary Stryker hip implant products have faced significant litigation. The Rejuvenate Hip Stem and ABG II Hip Stem were both recalled in July 2012 after reports of fretting and corrosion at the modular neck junction. The LFIT V40 Femoral Head reached a confidential settlement in November 2018 following claims that the component caused similar metallosis and tissue damage. most recently, the Tritanium Acetabular Shell has generated lawsuits since 2019, with over 200 complaints filed with the FDA’s MAUDE database””130 of which specifically involve loosening or implant migration. The Rejuvenate and ABG II devices shared a fundamental design flaw in their modular connection point.
Unlike traditional one-piece hip stems, these products featured a separate neck component that could be customized during surgery. While this modularity offered theoretical surgical advantages, the junction between components proved vulnerable to micro-motion, causing metal particles to shed into patients’ bodies. Stryker marketed these devices as innovations but pulled them from the market just four years after the Rejuvenate’s 2008 launch. A critical distinction exists between these products: the Rejuvenate, ABG II, and LFIT V40 have all reached settlement agreements, while Tritanium litigation remains unresolved. Patients with Tritanium implants face a different legal landscape, as no global settlement has been announced and the device has not been recalled despite documented failures.
The $1.43 Billion Rejuvenate and ABG II Settlement Explained
The fall 2014 global settlement for Rejuvenate and ABG II hip stems established a structured compensation program covering multiple phases. The initial phase set a November 2014 cutoff date for patients who had already undergone revision surgery. A second settlement phase announced in December 2016 extended coverage to patients whose revisions occurred after that initial deadline. By January 2021, Stryker reported that 96 percent of eligible patients had been reached for the third settlement period. Base awards of $300,000 per hip applied to most qualifying patients, though compensation could reach $600,000 or higher for those with extraordinary injuries.
The settlement structure included provisions that reduced payments for patients over 70 years of age, reflecting actuarial calculations about remaining life expectancy. However, even with age-related reductions, payouts remained substantial compared to typical product liability settlements. The original multidistrict litigation””MDL 2441″”consolidated 3,637 cases before Senior Judge Donovan W. Frank in the District of Minnesota. As of November 2025, only 42 cases remain pending, representing patients who either opted out of the settlement, filed late claims, or faced eligibility disputes. This dramatic reduction from thousands of cases to dozens demonstrates the settlement’s effectiveness in resolving the bulk of Rejuvenate and ABG II claims.
LFIT V40 Litigation and Confidential Settlement Terms
The LFIT V40 femoral head component spawned a separate wave of litigation consolidated as MDL 2768 before U.S. District Judge Indira Talwani in Massachusetts. Unlike the Rejuvenate’s modular neck issues, the LFIT V40 problems centered on the taper junction where the femoral head connects to the hip stem. Patients alleged that inadequate design and manufacturing tolerances caused fretting corrosion, releasing metal debris that destroyed surrounding bone and tissue.
Stryker announced a confidential settlement in November 2018, meaning specific compensation figures were not publicly disclosed. This confidentiality creates challenges for patients trying to evaluate their own claims, as they cannot directly compare potential outcomes to established benchmarks. As of November 2025, 68 cases remain pending in MDL 2768, suggesting ongoing disputes over eligibility or settlement terms. The confidential nature of the LFIT V40 resolution represents a strategic choice by Stryker to limit public disclosure of liability exposure. Patients considering LFIT V40 claims should understand that while a settlement mechanism exists, they may need to rely on their attorneys’ knowledge of unpublished terms rather than publicly available information about typical payouts.
Tritanium Acetabular Shell: The Ongoing Battle
Unlike the resolved Rejuvenate, ABG II, and LFIT V40 matters, Tritanium acetabular shell lawsuits remain active with no settlement in sight. The device received FDA approval through the 510(k) fast-track process in July 2008, allowing it to reach market without the rigorous clinical trials required for truly novel devices. Stryker demonstrated only that the Tritanium was substantially similar to previously approved products””a lower evidentiary threshold that critics argue fails to protect patients from unproven designs. Over 200 complaints have been filed with the FDA’s MAUDE database, with more than 130 specifically describing loosening or implant migration.
These reports detail patients whose acetabular cups failed to integrate with pelvic bone, requiring painful revision surgeries within years of initial implantation. Despite this documented failure pattern, the Tritanium has not been recalled and remains in clinical use. For patients with failing Tritanium implants, this creates a distinct situation. Without a recall, Stryker maintains that the device performs appropriately when properly implanted, potentially shifting blame toward surgical technique rather than product design. Plaintiffs must individually prove that their injuries resulted from device defects rather than other factors””a more demanding litigation posture than cases involving recalled products where the manufacturer has already acknowledged problems.
Eligibility Requirements and Compensation Factors
Qualifying for Stryker hip settlement compensation generally requires proof of revision surgery””a subsequent operation to remove or replace the defective implant. Medical records documenting the original implantation, symptoms experienced, diagnostic testing showing metal ion levels or tissue damage, and revision surgery details form the foundation of any claim. Patients who experienced complications but managed symptoms without revision may face significant eligibility hurdles. The $300,000 to $600,000 compensation range reflects multiple variables. Base awards start at $300,000 per affected hip, meaning bilateral implant recipients potentially qualify for double compensation.
Additional amounts apply for extraordinary injuries such as extensive bone loss, multiple revision surgeries, permanent disability, or complications from metallosis affecting organs beyond the hip joint. Conversely, patients over 70 may see reduced awards under formulas accounting for age-adjusted life expectancy. Comparison between Stryker settlements and other hip implant litigation provides context. The DePuy ASR hip settlement averaged roughly $250,000 per claim, while Biomet M2a Magnum settlements reportedly ranged from $200,000 to $300,000. Stryker’s $300,000 minimum positioned its resolution at the upper end of industry norms, though individual circumstances ultimately determine actual compensation.
Statute of Limitations and Filing Deadlines
Each state imposes different time limits for filing product liability claims, typically ranging from two to six years from discovery of injury. The statute of limitations clock generally begins when a patient knows or reasonably should know that their implant caused harm””not necessarily the date of original surgery. For example, a patient who experiences escalating hip pain for years before learning through blood testing that metallosis has occurred may have additional time to file. However, waiting creates substantial risks. Evidence deteriorates, medical records become harder to obtain, and memory fades.
Patients who underwent revision surgery years ago but never pursued legal action should consult an attorney immediately to assess whether their claims remain viable. Some states also impose “statutes of repose” that create absolute deadlines regardless of when injury was discovered. The settled MDL cases demonstrate that resolution can take years even after filing. Patients who joined the Rejuvenate/ABG II litigation in 2012 or 2013 waited until late 2014 for the settlement announcement, with actual payments extending years beyond. Those considering Tritanium claims face an even more uncertain timeline given the absence of any settlement framework.
What to Expect From the Legal Process
Pursuing a Stryker hip claim typically involves several stages. Initial case evaluation requires gathering medical records, operative reports, pathology findings from revision surgery, blood tests showing cobalt and chromium levels, and documentation of related medical expenses and lost income. Attorneys assess whether the evidence supports a viable claim before accepting cases. Most Stryker hip cases consolidated into multidistrict litigation, which streamlines pretrial proceedings but can extend timelines.
MDL proceedings handle common issues like expert testimony and document discovery collectively, but individual cases must still establish specific causation and damages. If global settlement negotiations succeed, participating plaintiffs receive offers based on standardized criteria; those who reject settlement terms retain the right to individual trial. Contingency fee arrangements allow most plaintiffs to pursue claims without upfront costs, with attorneys receiving a percentage””typically 33 to 40 percent””of any recovery. This structure means patients pay nothing if their case fails but share substantially in any settlement or verdict. Understanding fee structures before signing representation agreements helps manage expectations about net compensation.
Future of Stryker Hip Litigation
The remaining MDL cases””42 in the Rejuvenate/ABG II proceeding and 68 in the LFIT V40 matter””represent the litigation’s tail end for those devices. These residual cases involve plaintiffs who did not fit standard settlement criteria, disputed eligibility, or preferred pursuing individual claims. Their outcomes will not likely alter the broader settlement framework but may provide precedent for edge cases.
Tritanium litigation presents the primary unsettled front. Without a recall, Stryker maintains stronger defensive positioning, but continued adverse FDA reports and additional lawsuits may eventually pressure settlement discussions. Patients with Tritanium implants should monitor developments closely, as the litigation landscape could shift substantially depending on trial outcomes or regulatory action.
Conclusion
The Stryker hip replacement lawsuit saga underscores both the potential for significant compensation and the complexity of medical device litigation. With over $2 billion paid across multiple product lines, settlements have provided meaningful recovery for thousands of patients whose lives were disrupted by defective implants. The $300,000 to $600,000 individual payouts””particularly the record-setting $300,000 minimum for Rejuvenate and ABG II claims””established new benchmarks for hip implant litigation.
Patients experiencing complications with any Stryker hip device should consult qualified legal counsel to evaluate their options. Those with Rejuvenate, ABG II, or LFIT V40 implants may still qualify under existing settlement frameworks, while Tritanium recipients face evolving litigation without guaranteed resolution. Acting promptly preserves legal rights and maximizes the evidence available to support claims.